Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28071287 | 0.80 | RXRA (0.49) | KAT6ANOTUMKDM4EALDH1A1MAPK1 | |
| SCHEMBL873113 | 0.79 | MAPT (0.53) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL14964128 | 0.79 | MAPT (0.49) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL16787410 | 0.74 | KAT6A (0.46) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL526836 | 0.71 | ALDH1A1 (0.47) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL6209994 | 0.71 | MAPT (0.43) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL387290 | 0.71 | MAPT (0.47) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL25753316 | 0.71 | KAT6A (0.41) | KAT6AMAPTNOTUMGRM5KDM4E | |
| SCHEMBL16960385 | 0.71 | ALDH1A1 (0.41) | MAPTKDM4EALDH1A1MAPK1KMT2A | |
| SCHEMBL16950695 | 0.71 | MAPT (0.36) | MAPTKDM4EALDH1A1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | KAT6A 573/4885MAPT 3157/4885NOTUM 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.